Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Minnelide™ Capsules Alone and in Combination With Paclitaxel in Advanced Gastric Cancer
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Minneamrita Therapeutics LLC
- Target Recruit Count
- 36
- Registration Number
- NCT05566834
- Locations
- 🇰🇷
Samsung Medical Center, Soeul, Korea, Republic of
Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas
- Conditions
- Metastatic Adenocarcinoma of the Pancreas
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Minneamrita Therapeutics LLC
- Target Recruit Count
- 36
- Registration Number
- NCT05557851
- Locations
- 🇰🇷
Samsung Medical Center, Soeul, Korea, Republic of
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
- Conditions
- Advanced CancerBreast CancerPancreatic CancerProstate Cancer MetastaticSolid Carcinoma of StomachCancer of StomachColo-rectal CancerSolid TumorGastric CancerSolid Carcinoma
- Interventions
- Drug: Minnelide™Capsules
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Minneamrita Therapeutics LLC
- Target Recruit Count
- 66
- Registration Number
- NCT03129139
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Minneamrita Therapeutics LLC
- Target Recruit Count
- 19
- Registration Number
- NCT03117920
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study of Minnelide™ in Patients With Advanced GI Tumors
- Conditions
- Advanced Gastrointestinal Tumors
- Interventions
- Drug: Minnelide™ 001
- First Posted Date
- 2013-08-23
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Minneamrita Therapeutics LLC
- Target Recruit Count
- 45
- Registration Number
- NCT01927965
- Locations
- 🇺🇸
Virginia G. Piper Cancer Center at Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸University of Minnesota Masonic Cancer Clinic, Minneapolis, Minnesota, United States